Altered peptide ligand design: Altering immune responses to class I MHC/peptide complexes

Immunological Reviews

Volumn 163, Issue , 1998, Pages 151-160

  Collins, Edward J ^a   Frelinger, Jeffrey A ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ANTIGEN BINDING; CELL SURFACE; IMMUNE RESPONSE; IMMUNOGENICITY; PRIORITY JOURNAL; REVIEW;

ANTIGEN PRESENTATION; HISTOCOMPATIBILITY ANTIGENS CLASS I; IMMUNOGLOBULIN HEAVY CHAINS; LIGANDS; LYMPHOCYTE ACTIVATION; MUTATION; PEPTIDES; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0031819187     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1998.tb01194.x     Document Type: Review

References (66)

1. Townsend AR, Gotch FM, Davey J. Cytotoxic T cells recognize fragments of the influenza nucleoprotein. Cell 1985;42:457-467.
2. Klein J. Natural history of the Major Histocompatibility Complex. New York: Wiley-Interscience; 1986.
3. Allison JP. CD28-B7 interactions in T-cell activation. Curr Opin Immunol 1994;6:414-419.
4. Blieden TM, McAdam AJ, Frelinger JG, Lord EM. Mechanism of cytolytic T lymphocyte killing of a low class I-expressing tumor. J Immunol 1991;147:1433-1438.
5. Pulaski BA, et al. Interleukin 3 enhances cytotoxic T lymphocyte development and class I major histocompatibility complex "representation" of exogenous antigen by tumor-infiltrating antigen-presenting cells. Proc Natl Acad Sci USA 1996;93:3669-3674.
6. McAdam AJ, et al. Analysis of the effect of cytokines (interleukins 2, 3, 4, and 6, granulocyte-monocyte colony-stimulating factor, and interferon-gamma) on generation of primary cytotoxic T lymphocytes against a weakly immunogenic tumor. Cell Immunol 1995;165:183-192.
7. Pogue RR, Eron J, Frelinger JA, Matsui M. Amino-terminal alteration of the HLA-A*0201-restricted human immunodeficiency virus pol peptide increases complex stability and in vitro immunogenicity. Proc Natl Acad Sci USA 1995;92:8166-8170.
8. Alam SM, et al. T-cell-receptor affinity and thymocyte positive selection. Nature 1996;381:616-620.
9. Viola A, Lanzavecchia A. T cell activation determined by T cell receptor number and tunable thresholds. Science 1996;273:104-106.
10. Garcia KC, et al. Structural basis of plasticity in T cell receptor recognition of a self peptide-MHC antigen. Science 1998;279:1166-1172.
11. Batalia MA, Collins EJ. Peptide binding by class I and class II MHC molecules. Biopolymers 1997;43:281-302.
12. Madden DR, Gorga JC, Strominger JL, Wiley DC. The three-dimensional structure of HLA-B27 at 2.1 A resolution suggests a general mechanism for tight peptide binding to MHC Cell 1992;70:1035-1048.
13. Bouvier M, Wiley DC. Importance of peptide amino and carboxyl termini to the stability of MHC class I molecules. Science 1994;265:398-402.
14. Colbert RA, Rowland JSL, McMichael AJ, Frelinger JA. Allele-specific B pocket transplant in class I major histocompatibility complex protein changes requirement for anchor residue at P2 of peptide. Proc Natl Acad Sci USA 1993;90:6879-6883.
15. Griffin TA, et al. Naturally occurring A pocket polymorphism in HLA-B*2703 increases the dependence on an accessory anchor residue at P1 for optimal binding of nonamer peptides. J Immunol 1997;159:4887-4897.
16. Guo HC, et al. Comparison of the P2 specificity pocket in three human histocompatibility antigens: HLA-A*6801, HLA-A*0201, and HLA-B*2705. Proc Natl Acad Sci USA 1993;90:8053-8057.
17. Garrett TP, Saper MA, Bjorkman PJ, Strominger JL, Wiley DC. Specificity pockets for the side chains of peptide antigens in HLA-Aw68. Nature 1989;342:692-696.
18. Fahnestock ML, et al. Effects of peptide length and composition on binding to an empty class I MHC heterodimer. Biochemistry 1994;33:8149-8158.
19. Bouvier M, Wiley DC. Importance of Antigenic peptide N- and C-termini to the stability of class I MHC molecules. Science 1994;265:398-402.
20. Gotch F, McMichael A, Rothbard J. Recognition of influenza A matrix protein by HLA-A2-restricted cytotoxic T lymphocytes. Use of analogues to orientate the matrix peptide in the HLA-A2 binding site. J Exp Med 1988;168:2045-2057.
21. Hioe CE, Frelinger JA. Alterations of a dominant epitope of lymphocytic choriomeningitis virus which affect class I binding and cytotoxic T cell recognition. Mol Immunol 1995;32:725-731.
22. Davis MM, Bjorkman PJ. T-cell antigen receptor genes and T-cell recognitions. Nature 1988;334:395-402.
23. Zerrahn J, Held W, Raulet DH. The MHC reactivity of the T cell repertoire prior to positive and negative selection. Cell 1997;88:627-636.
24. Loftus DJ, Chen Y, Covell DG, Engelhard VH, Appella E. Differential contact of disparate class I/peptide complexes as the basis for epitope cross-recognition by a single T cell receptor. J Immunol 1997;158:3651-3658.
25. Penna A, et al. Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen. J Exp Med 1991;174:1565-1570.
26. Ruppert J, Sidney J, Celis E, Kubo RT, Grey HM, Sette A. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 1993;74:929-937.
27. Colbert RA, Rowland-Jones SL, McMichael AJ, Frelinger JA. Differences in peptide presentation between B27 subtypes: the importance of the P1 side chain in maintaining high affinity peptide binding to B*2703. Immunity 1994;1:121-130.
28. Sette A, et al. Peptide binding to the most frequent HLA-A class I alleles measured by quantitative molecular binding assays. Mol Immunol 1994;31:813-822.
29. Ruppert J, Sidney J, Celis E, Kubo RT, Grey HM, Sette A. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 1993;74:929-937.
30. Falk K, Rotzschke O, Stevanovic S, Jung G, Rammensee HG. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 1991;351:290-296.
31. Urban RG, et al. A subset of HLA-B27 molecules contains peptides much longer than nonamers. Proc Natl Acad Sci USA 1994;91:1534-1538.
32. Smith K, Reid S, McMichael A, Stuart D, Bell J, Jones Y. Bound water structure and polymorphic amino acids act together to allow the binding of different peptides to MHC class I HLA-B53. Immunity 1996;4:215-228.
33. Takamiya Y, et al. HLA-B*3501-peptide interactions: role of anchor residues of peptides in their binding to HLA-B*3501 molecules. Int Immunol 1994;6:255-261.
34. Saper MA, Bjorkman PJ, Wiley DC. Refined structure of the human histocompatibility antigen HLA-A2 at 2.6 Å resolution. J Mol Biol 1991;219:277-319.
35. Silver ML, Guo HC, Strominger JL, Wiley DC. Atomic structure of a human MHC molecule presenting an influenza virus peptide. Nature 1992;360:367-369.
36. Madden DR, Garboczi DN, Wiley DC. The antigenic identity of peptide-MHC complexes: a comparison of the conformations of five viral peptides presented by HLA-A2. Cell 1993;75:693-708.
37. Collins EJ, Garboczi DN, Karpusas MN, Wiley DC. The three-dimensional structure of a class I major histocompatibility complex molecule missing the alpha 3 domain of the heavy chain. Proc Natl Acad Sci USA 1995;92:1218-1221.
38. Collins EJ, Garboczi DN, Wiley DC. Three-dimensional structure of a peptide extending from one end of a class I MHC binding site. Nature 1994;371:626-629.
39. Garboczi DN, Ghosh P, Utz U, Fan QR, Biddison WE, Wiley DC. Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. Nature 1996;384:134-141.
40. Corr M, et al. T cell receptor-MHC class I peptide interactions: affinity, kinetics, and specificity. Science 1994;265:946-949.
41. Stanfield RL, Takimoro-Kamimura M, Rini JM, Profy AT, Wilson IA. Major antigen-induced domain rearrangements in an antibody. Structure 1993;1:83-93.
42. Garrett TP, Saper MA, Bjorkman PJ, Strominger JL, Wiley DC. Specificity pockets for the side chains of peptide antigens in HLA-Aw68. Nature 1989;342:692-696.
43. Baldwin E, Xu J, Hajiseyedjavadi O, Baase WA, Matthews BW. Thermodynamic and structural compensation in "size-switch" core repacking variants of bacteriophage T4 lysozyme. J Mol Biol 1996;259:542-559.
44. Reid SW, et al. Antagonist HIV-1 Gag peptides induce structural changes in HLA B8. J Exp Med 1996;184:2279-2286.
45. Sloan-Lancaster J, Allen PM. Altered peptide ligand-induced partial T cell activation: molecular mechanisms and role in T cell biology. Annu Rev Immunol 1996;14:1-27.
46. Garcia KC, et al. CD8 enhances formation of stable T-cell receptor/MHC class I molecule complexes. Nature 1996;384:577-581.
47. Gao GF, et al. Crystal structure of the complex between human CD8alpha and HLA-A2. Nature 1997;387:630-634.
48. Salter RD, et al. A binding site for the T-cell co-receptor CD8 on the alpha 3 domain of HLA-A2. Nature 1990;345:41-46.
49. Giblin PA, Leahy DJ, Mennone J, Kavathas PB. The role of charge and multiple faces of the CD8 alpha/alpha homodimer in binding to major histocompatibility complex class I molecules: support for a bivalent model. Proc Natl Acad Sci USA 1994;91:1716-1720.
50. Parker KC, DiBrino M, Hull L, Coligan JE. The beta 2-microglobulin dissociation rate is an accurate measure of the stability of MHC class I heterotrimers and depends on which peptide is bound. J Immunol 1992;149:1896-1904.
51. Koopmann JO, Hammerling GJ, Momburg F. Generation, intracellular transport and loading of peptides associated with MHC class I molecules. Curr Opin Immunol 1997;9:80-88.
52. York IA, Rock KL. Antigen processing and presentation by the class I major histocompatibility complex. Annu Rev Immunol 1996;14:369-396.
53. Lehner PJ, Cresswell P. Processing and delivery of peptides presented by MHC class I molecules. Curr Opin Immunol 1996;8:59-67.
54. Ortmann B, et al. A critical role for tapasin in the assembly and function of multimeric MHC class I-TAP complexes. Science 1997;277:1306-1309.
55. Li S, Sjogren HO, Hellman U, Pettersson RF, Wang P. Cloning and functional characterization of a subunit of the transporter associated with antigen processing. Proc Natl Acad Sci USA 1997;94:8708-8713.
56. Solheim JC, Harris MR, Kindle CS, Hansen TH. Prominence of beta 2-microglobulin, class I heavy chain conformation, and tapasin in the interactions of class I heavy chain with calreticulin and the transporter associated with antigen processing. J Immunol 1997;158:2236-2241.
57. Momburg F, Roelse J, Howard JC, Butcher GW, Hammerling GJ, Neefjes JJ. Selectivity of MHC-encoded peptide transporters from human, mouse and rat. Nature 1994;367:648-651.
58. Lewis JW, Neisig A, Neefjes J, Elliott T. Point mutations in the alpha 2 domain of HLA-A2.1 define a functionally relevant interaction with TAP. Curr Biol 1996;6:873-883.
59. Peace-Brewer A, Tussey L, Matsui M, Li G, Quinn D, Frelinger J. A point mutation in HLA-A*0210 results in failure to bind the TAP complex and to present virus-derived peptides to CTL. Immunity 1996;4:505-514.
60. d binding motif identification. Pept Res 1995;8:44-51.
61. Abastado JP, Casrouge A, Kourilsky P. Differential role of conserved and polymorphic residues of the binding groove of MHC class I molecules in the selection of peptides. J Immunol 1993;151:3569-3575.
62. Schumacher TN, et al. Synthetic peptide libraries in the determination of T cell epitopes and peptide binding specificity of class I molecules. Eur J Immunol 1992;22:1405-1412.
63. b. J Biol Chem 1995;270:24130-24134.
64. Hunt DF, et al. Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science 1992;255:1261-1263.
65. Frelinger JA, McMillan M. The role of peptide specificity in MHC class I-restricted allogeneic responses. Immunol Rev 1996;154:45-58.
66. Tussey LG, Matsui M, Rowland JS, Warburton R, Frelinger JA, McMichael A. Analysis of mutant HLA-A2 molecules. Differential effects on peptide binding and CTL recognition. J Immunol 1994;152:1213-1221.